21:22 , Jan 31, 2019 |  BC Innovations  |  Emerging Company Profile

Apic: Dual-gene therapies

Apic Bio Inc.'s APB-101 is a dual-function gene therapy for AAT deficiency that silences the mutant AAT gene and augments wild-type AAT expression, which the company believes gives it greater efficacy and lower liver toxicity...
17:41 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) and cancer company Stelexis Therapeutics LLC (New York, N.Y.) each announced series A rounds of at least $40 million. Other companies that announced venture rounds include Biond...
23:42 , Jan 8, 2019 |  BC Extra  |  Financial News

Venture roundup: Apic, Stelexis, Biond, Keros

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) and cancer company Stelexis Therapeutics LLC (New York, N.Y.) each announced series A rounds this week of at least $40 million. Other companies that announced venture rounds...
15:09 , Sep 1, 2017 |  BC Week In Review  |  Financial News

AAT deficiency newco Apic Bio launches

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) launched Aug. 22 with an undisclosed investment from the Alpha-1 Foundation and private investor Ed Krapels, who has alpha-1 antitrypsin ( AAT ; A1AT; SERPINA1) deficiency. The...
22:44 , Aug 22, 2017 |  BC Extra  |  Financial News

AAT deficiency newco Apic Bio launches

Gene therapy company Apic Bio Inc. (Cambridge, Mass.) launched Tuesday with an undisclosed investment from the Alpha-1 Foundation and private investor Ed Krapels, who has alpha-1 antitrypsin ( AAT ; A1AT ; SERPINA1) deficiency. The...